PMID- 20352440
OWN - NLM
STAT- MEDLINE
DCOM- 20100917
LR  - 20220311
IS  - 1435-702X (Electronic)
IS  - 0721-832X (Linking)
VI  - 248
IP  - 9
DP  - 2010 Sep
TI  - Factors influencing visual outcome of polypoidal choroidal vasculopathy one year 
      after photodynamic therapy.
PG  - 1233-9
LID - 10.1007/s00417-010-1365-2 [doi]
AB  - BACKGROUND: Polypoidal choroidal vasculopathy (PCV) is considered to be a good 
      indication for photodynamic therapy (PDT). We evaluated pre-PDT factors 
      predicting better visual acuity (VA) 1 year after PDT in patients with PCV. 
      METHODS: We evaluated 181 eyes of 181 patients who underwent PDT and were 
      followed up for 1 year. Additional treatments, if needed, were given every 3 
      months, with a maximum of four PDT sessions, for up to 9 months. We compared 
      best-corrected VA (BCVA) 1 year after PDT with that before PDT. Pre-PDT factors 
      favoring better BCVA 1 year after PDT were evaluated using stepwise multiple 
      regression analysis. RESULTS: Mean BCVA improved from 0.29 +/- 0.15 before PDT to 
      0.43 +/- 0.32 1 year after PDT (p < 0.001). BCVA improved in 55 eyes (30.4%), and 
      was maintained in 110 (60.8%). Pre-PDT factors predicting better BCVA at 1 year 
      were better initial BCVA (beta = 0.271, p < 0.001) within our eligibility 
      criteria up to 0.6, a relatively small diameter of a network of vessels plus 
      polypoidal lesions on indocyanine green angiography (beta = 0.249, p < 0.001), 
      and the absence of a polypoidal lesion under the fovea (beta = 0.175, p = 0.011). 
      CONCLUSION: Better BCVA can be expected 1 year after PDT in eyes with PCV showing 
      better initial BCVA, relatively small lesions on indocyanine green angiography, 
      and no subfoveal polypoidal lesion before PDT.
FAU - Mori, Ryusaburo
AU  - Mori R
AD  - Department of Ophthalmology, Nihon University, School of Medicine, Surugadai 
      Nihon University Hospital, 1-8-13 Surugadai, Kanda, Chiyoda-ku, Tokyo, Japan.
FAU - Yuzawa, Mitsuko
AU  - Yuzawa M
FAU - Lee, Zeon
AU  - Lee Z
FAU - Haruyama, Miho
AU  - Haruyama M
FAU - Akaza, Eriko
AU  - Akaza E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100330
PL  - Germany
TA  - Graefes Arch Clin Exp Ophthalmol
JT  - Graefe's archive for clinical and experimental ophthalmology = Albrecht von 
      Graefes Archiv fur klinische und experimentelle Ophthalmologie
JID - 8205248
RN  - 0 (Coloring Agents)
RN  - IX6J1063HV (Indocyanine Green)
SB  - IM
CIN - Graefes Arch Clin Exp Ophthalmol. 2011 May;249(5):791; author reply 793. PMID: 
      20689963
MH  - Aged
MH  - Aged, 80 and over
MH  - Choroid/*blood supply
MH  - Choroid Diseases/*drug therapy/physiopathology
MH  - Coloring Agents
MH  - Female
MH  - Fluorescein Angiography
MH  - Follow-Up Studies
MH  - Humans
MH  - Indocyanine Green
MH  - Male
MH  - Middle Aged
MH  - Peripheral Vascular Diseases/*drug therapy/physiopathology
MH  - *Photochemotherapy
MH  - Tomography, Optical Coherence
MH  - Treatment Outcome
MH  - Visual Acuity/*physiology
EDAT- 2010/03/31 06:00
MHDA- 2010/09/21 06:00
CRDT- 2010/03/31 06:00
PHST- 2009/11/10 00:00 [received]
PHST- 2010/03/11 00:00 [accepted]
PHST- 2010/02/24 00:00 [revised]
PHST- 2010/03/31 06:00 [entrez]
PHST- 2010/03/31 06:00 [pubmed]
PHST- 2010/09/21 06:00 [medline]
AID - 10.1007/s00417-010-1365-2 [doi]
PST - ppublish
SO  - Graefes Arch Clin Exp Ophthalmol. 2010 Sep;248(9):1233-9. doi: 
      10.1007/s00417-010-1365-2. Epub 2010 Mar 30.